Eyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19)

Eyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19) | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Eyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19) Hashim Ali Khan, Muhammad Aamir Shahzad, Junaid Iqbal, Sohail Abbas Juwa, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-203200/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 09 Jan, 2022 Read the published version in SN Comprehensive Clinical Medicine → Version 1 posted You are reading this latest preprint version Abstract Purpose To report the eyelid myokymia in patients recovered from COVID-19 disease. Methods A cohort of 15 patients who developed eyelid myokymia during or immediate post-recovery of systemic disease were evaluated. Demographic, clinical characteristics, effect of age, and hospitalization on the disease course were studied. The disease course was evaluated every month for 3 months period. Results All, except 2, patients had complete resolution of lid myokymia within 3 months of onset. Mean ± SD myokymia recovery time was 44.1 ± 20.9 Days. Gender had no impact on the duration of disease. Age and duration of hospitalization had a strong positive correlation with myokymia recovery time (r = 0.8, p = 0.001 and r = 0.8, p = 0.01). Conclusion Eyelid myokymia may involve COVID-19 patients during or immediately after systemic recovery. While myokymia recovers gradually in all these patients; older age and longer duration of hospitalization are associated with slower recovery. Ophthalmology COVID-19 eyelid myokymia corona virus blepharospasm Figures Figure 1 Figure 2 Introduction Coronavirus disease 2019 (COVID-19) is the spectrum of clinical manifestations caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a member of Coronaviridae family.[1] The rapid transmission of the virus has caused a global pandemic with 91.8 million cases and 1.97 million deaths globally.[2] While respiratory disease caused by this virus has been most emphasized; the virus may also affect other body systems and function. Ocular manifestations of SARS-CoV-2 have been described by several investigators. While ocular surface disease is the most common ophthalmic manifestation of this virus; retinal vascular changes, neuro-ophthalmological complication, and uveal inflammation are also seen in a small number of patients.[3-5] Eyelid myokymia is the most common type of facial myokymias seen in otherwise healthy individuals. It is a self-limiting benign condition seen involuntary, fine, continuous, undulating contractions of orbicularis oculi muscles and may be associated with anxiety, depression, heavy caffeine intake and drugs.[6-8] Nevertheless, there are no reports in literature at this time, to the best of our knowledge, about the eyelid myokymia in COVID-19 patients. The objective of our study was to describe features of lid myokymia developed during or immediately after the recovery from systemic disease. Methods In this multicenter study, a cohort of patients who developed eyelid twitching during or after COVID-19 infection was recruited. Inclusion criteria were (1) New-onset eyelid twitching during or after active COVID-19 infection (2) age between 18 and 70 years, (3) Documented evidence of recovery from COVID-19 infection, We excluded patients who had (1) History of eyelid twitching within past 1 year, (2) history of ocular surgery or trauma within the past one year, (3) family history of essential blepharospasm or hemifacial spasm, (4) history of any ocular disease including glaucoma, uveitis or ocular surface disorders, and (5) history of head/ face trauma or any known neurological disease. All, time intervals were calculated from the date of discharge from hospital or documented recovery of systemic infection. Each patient was evaluated at baseline and every month for 3 months. Comprehensive ophthalmic and neurological assessments including complete cranial nerve assessments were performed at each visit. Eyelid myokymia was defined as episodic or persistent fine, spontaneous undulating contraction involving any of upper or lower lids. The rate of occurrence was reported by the patient and graded as (1) most of the time, (2) half of the time, (3) sometimes or (4) none of the time. Resolution of lid myokymia was defined as the patient-reported complete absence of lid twitch for 2 weeks. Myokymia recovery time was the interval between the systemic disease recovery and complete resolution of myokymia Data analysis; Microsoft Excel was used for data collection and handling while Statistical analysis was performed using statistical software (SPSS software Version 21; SPSS, Inc., Chicago, IL, USA). Data were presented as mean ±SD for quantitative variables and as counts (percentages) for categorical variables. Shapiro–Wilk test was used to analyze the normal distribution of data. The effect of gender and hospital admission on ocular recovery interval was tested. The relationship between length of hospital stay and ocular recovery time was analyzed using Pearson ( r ) correlation. P values of < 0.05 were considered as statistically significant. Results A total of 15 patients, 9 (60%) males, were included. Mean± SD age was 48.3 ± 7.9 (range 38 t0 62) years. There was no difference in age between males and females (P=0.81). Ten (66.7%) patients, 3 females and 7 males, had a history of hospital admission for management of COVID 19 disease. Mean duration of hospital stay was 6.7± 2.98 days (Range 3.0 to 13) while females had a shorter hospital stay 7.4±3.21 days vs 5.0±1.7 days (P=0.41). Five (33.3%) patients had a history of conjunctivitis during active systemic disease. All patients experienced lid myokymia during or immediately after the systemic disease recovery. None of them had any neurological signs/ symptoms during or before the current study. Interval between systemic disease recovery baseline ocular examination was 13.1 ± 4.5 days (range 7 to 21). Patient demographics and clinical characteristics are shown in table 1. Table 1: Patient demographics, clinical characteristics and myokymia recovery time Patient Age/Sex Hospitalized /days Ocular Examination Conjunctivitis Recovery time Days 1 38/M Yes/ 3 19 Yes 31 2 44/F Yes/ 4 17 Yes 60 3 41/F No/0 11 Yes 21 4 42/F No/0 10 Yes 33 5 62/M Yes/13 10 No Didn’t recover* 6 61/F Yes/7 15 No Didn’t recover* 7 46/M Yes/6 21 No 49 8 47/M Yes/5 11 No 42 9 53/M Yes/8 8 No 88 10 55/M Yes/9 7 No 62 11 57/M Yes/8 18 No 67 12 51/M No/0 15 No 43 13 40/F No/0 16 Yes 18 14 49/F Yes/4 10 No 40 15 39/M No/0 8 No 19 *Did not recover till the end point of current study At baseline, most patients had been experiencing lid myokymia half of the time or most of the time. At one-month follow-up, most patients had been experiencing myokymia sometimes while 11 patients (73%) had complete resolution at two months follow-up. Thirteen patients (86.7%) had complete resolution at 3 months follow up. Figure 1 shows the disease course in the current study. Complete recovery of lid myokymia was observed in 13 (87%) patients at three months post COVID-19 recovery. The interval between systemic disease recovery and complete resolution of lid myokymia was 44.1± 20.84 days. Two patients (1 male), did not report any improvement or deterioration of twitch at three months. Magnetic resonance imaging of the brain in those patients was unremarkable. Myokymia recovery interval was independent of the history of conjunctivitis (P=0.45) and gender (P=0.2). There was a strong positive correlation between age and myokymia recovery time ( r = 0.8, P=0.001). Length of hospitalization also had a positive correlation with myokymia recovery time ( r= 0.8, P= 0.01). Myokymia recovery time was independent of gender (t=1.5, df=11, P=0.2). Figure 2 shows the impact of age and duration of hospitalization on ocular recovery time. Discussion Common ocular complications/ manifestations of COVID-19 include dry eye, non-specific conjunctivitis, and retinal vascular changes. The exact incidence of these complications is yet to be determined. However, ocular surface disorders including conjunctivitis and dry eye are most frequently reported in COVID-19 patients.[5,9,10,3] Non-specific conjunctivitis, including conjunctival hyperemia, lacrimation, follicular conjunctivitis, ocular pain have been reported in 5 to 31% of patients.[11-14] While ocular surface diseases ranging from conjunctivitis to keratopathy was seen in up to 60% of critically ill patients.[15,16] Other relatively common ocular manifestations of SARS-CoV-2 include keratoconjunctivitis, epithelial defects subepithelial infiltrates and pseudodendrites.[17,18,10] Granulomatous anterior uveitis, retinal detachment, retinal vasculitis, retinitis, and retinal degenerations are seen in animal studies.[4,5,10] In a study of 54 COVID-19 patients, dilatation of retinal veins and vascular tortuosity were most common and seen in 27.7% and 12.9% of patients. Other changes included retinal hemorrhages in 9.25% and cotton wool spots in 7.4% of patients.[17] Another study reported hyperreflective foci in the macula of 12 COVID-19 patients using optical coherence tomography. Besides OCT findings, 4 patients had cotton wool spots and retinal microhemorrhages.[18] Concerns about the potential misinterpretation of these results have recently been posed, signifying that hyperreflective areas could merely represent normal retinal vessels.[19,20] Retinal vein occlusion and valsalva retinopathy are rare potential associations of COVID-19.[11] Neuroophthalmological associations of SARS-CoV-2 are rare. A limited number of case reports have described Miller Fisher syndrome, Guillain-Barré syndrome, polyneuritis cranialis, internuclear ophthalmoparesis and oculomotor palsy.[5] Meningitis, encephalomyelitis and encephalopathy may also affect these patients.[10,21] The primary outcome of the present study was to evaluate the pattern of eyelid myokymia presumably associated with COVID-19 and to the best of our knowledge, it is the first study to reporting eyelid myokymia as a potential association of SARS-CoV-2 infection. We included all patients who experienced lid twitching during or after recovery from covid-19 infection. The frequency/rate of myokymia gradually declined over time to total resolution and most patients completely recovered within two months of recovery from systemic disease. Older age and longer hospital stay were associated with prolongation of lid myokymia while the history of conjunctivitis had no impact on the time for recovery of myokymia. Eyelid myokymia results from doublets or triplets of spontaneous non-synchronous discharges of adjacent motor units at a 30 to 70 Hz rate with inter-discharge intervals of 100-200 ms.[8,22] It is most common of all facial myokymias, typically unilateral with a tendency for lower lid and limited to orbicularis oculi muscle. It is a self-limiting benign condition affecting otherwise healthy individuals at any age and resolves completely over days to months.[23,8,6] Nonetheless stress, anxiety, excessive caffeine intake and administration of topiramate are known associations.[24,7,8] Rarely it may be associated with Guillain‐Barre syndrome and multiple sclerosis.[25,26] Mental illness including anxiety and depression are common, affecting roughly 1/4 th to half of the COVID-19 survivors, immediate post-recovery and may persist for long. The incidence of mental illness was greater in hospitalized patients.[27,28,1,29,30] None of our patients had a recent history of topiramate intake or heavy caffeine consumption. Nonetheless, eyelid myokymia in our cohort of patients is attributable to anxiety or presumably it is a manifestation of SARS-CoV-2 infection itself. Akin to classic eyelid myokymia, there was a gradual recovery of myokymia in our patients. While older age and hospitalization were associated with slower resolution of the disease. References Yamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, Cushing TR, Hopp L, Tiwari A, Hariri R, Sokolov R, Wheeler C, Kaushik A, Elsayegh A, Eliashiv D, Hedrick R, Jafari B, Johnson JP, Khorsandi M, Gonzalez N, Balakhani G, Lahiri S, Ghavidel K, Amaya M, Kloor H, Hussain N, Huang E, Cormier J, Wesson Ashford J, Wang JC, Yaghobian S, Khorrami P, Shamloo B, Moon C, Shadi P, Kateb B (2020) COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. J Alzheimers Dis 77 (2):459-504. doi:10.3233/jad-200831 WHO Coronavirus Disease (COVID-19) Dashboard. (2021). https://covid19.who.int/ . Accessed 12/01/2021 2021 Bostanci Ceran B, Ozates S (2020) Ocular manifestations of coronavirus disease 2019. Graefes Arch Clin Exp Ophthalmol 258 (9):1959-1963. doi:10.1007/s00417-020-04777-7 Seah I, Agrawal R (2020) Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm 28 (3):391-395. doi:10.1080/09273948.2020.1738501 Bertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, Gambato T, Lanzetta P (2020) Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. J Ophthalmol 2020:4827304. doi:10.1155/2020/4827304 Banik R, Miller NR (2004) Chronic Myokymia Limited to the Eyelid Is a Benign Condition. J Neuroophthalmol 24 (4):290-292 Khalkhali M (2016) Topiramate-Induced Persistent Eyelid Myokymia. Case Reports in Psychiatry 2016:7901085. doi:10.1155/2016/7901085 Miller NR (2011) Eyelid Myokymia. Surv Ophthalmol 56 (3):277-278. doi:10.1016/j.survophthal.2011.02.005 Sun S, Su W, Lin CQ, Li X, Yan H, Tian B, Lin H (2020) COVID-19: the novel coronavirus disease and its manifestations and management in ophthalmology. Discov Med 29 (158):145-157 Ho D, Low R, Tong L, Gupta V, Veeraraghavan A, Agrawal R (2020) COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations. Ocul Immunol Inflamm 28 (5):726-734. doi:10.1080/09273948.2020.1772313 Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K (2020) Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 138 (5):575-578. doi:10.1001/jamaophthalmol.2020.1291 Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, Qin Y, Xiao K, Zhang H, Sun X (2020) Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol 98 (8):e951-e959. doi:10.1111/aos.14472 Güemes-Villahoz N, Burgos-Blasco B, García-Feijoó J, Sáenz-Francés F, Arriola-Villalobos P, Martinez-de-la-Casa JM, Benítez-Del-Castillo JM, Herrera de la Muela M (2020) Conjunctivitis in COVID-19 patients: frequency and clinical presentation. Graefes Arch Clin Exp Ophthalmol 258 (11):2501-2507. doi:10.1007/s00417-020-04916-0 Sindhuja K, Lomi N, Asif MI, Tandon R (2020) Clinical profile and prevalence of conjunctivitis in mild COVID-19 patients in a tertiary care COVID-19 hospital: A retrospective cross-sectional study. Indian J Ophthalmol 68 (8):1546-1550. doi:10.4103/ijo.IJO_1319_20 Saritas TB, Bozkurt B, Simsek B, Cakmak Z, Ozdemir M, Yosunkaya A (2013) Ocular Surface Disorders in Intensive Care Unit Patients. Scientific World Journal 2013:182038. doi:10.1155/2013/182038 Mercieca F, Suresh P, Morton A, Tullo A (1999) Ocular surface disease in intensive care unit patients. Eye 13 (2):231-236. doi:10.1038/eye.1999.57 Invernizzi A, Torre A, Parrulli S, Zicarelli F, Schiuma M, Colombo V, Giacomelli A, Cigada M, Milazzo L, Ridolfo A, Faggion I, Cordier L, Oldani M, Marini S, Villa P, Rizzardini G, Galli M, Antinori S, Staurenghi G, Meroni L (2020) Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine 27. doi:10.1016/j.eclinm.2020.100550 Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R, Jr. (2020) Retinal findings in patients with COVID-19. The Lancet 395 (10237):1610. doi:10.1016/S0140-6736(20)31014-X Khan HA, Shahzad MA, Awan MA, Marashi A (2020) Perspective on retinal findings in COVID-19. Adv Ophthalmol Vis Syst 10 (5):121-122 Vavvas DG, Sarraf D, Sadda SR, Eliott D, Ehlers JP, Waheed NK, Morizane Y, Sakamoto T, Tsilimbaris M, Miller JB (2020) Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication. Eye 34 (12):2153-2154. doi:10.1038/s41433-020-1084-9 Yavarpour-Bali H, Ghasemi-Kasman M (2020) Update on neurological manifestations of COVID-19. Life sciences 257:118063-118063. doi:10.1016/j.lfs.2020.118063 Horowitz SH (1987) Hemifacial spasm and facial myokymia: electrophysiological findings. Muscle Nerve 10 (5):422-427. doi:10.1002/mus.880100508 Kim L, Levine B, Lelli G (2010) Recognition and treatment of benign essential blepharospasm and its variants. Contemporary Ophthalmology 9 (6):1-5 Medrano-Martínez V, Pérez-Sempere A, Moltó-Jordá JM, Fernández-Izquierdo S, Francés-Pont I, Mallada-Frechin J, Piqueras-Rodríguez L (2015) Eyelid myokymia in patients with migraine taking topiramate. Acta Neurol Scand 132 (2):143-146. doi: https://doi.org/10.1111/ane.12395 Palasí A, Martínez-Sánchez N, Bau L, Campdelacreu J (2013) Unilateral eyelid myokymia as a form of presentation of multiple sclerosis. Neurología (English Edition) 28 (3):187-189. doi:10.1016/j.nrleng.2011.09.009 Van Zandycke M, Martin J-J, Gaer LV, Van den Heyning P (1982) Facial myokymia in the Guillain‐Barre syndrome: A clinicopathologic study. Neurology 32 (7):744-744 Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P, group C-BOCS, Benedetti F (2020) Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun 89:594-600. doi:10.1016/j.bbi.2020.07.037 Dai L-L, Wang X, Jiang T-C, Li P-F, Wang Y, Wu S-J, Jia L-Q, Liu M, An L, Cheng Z (2020) Anxiety and depressive symptoms among COVID-19 patients in Jianghan Fangcang Shelter Hospital in Wuhan, China. PLoS One 15 (8):e0238416. doi:10.1371/journal.pone.0238416 Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7 (7):611-627. doi:10.1016/S2215-0366(20)30203-0 Keyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M (2020) SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. J Neuroimmunol 350:577436-577436. doi:10.1016/j.jneuroim.2020.577436 Cite Share Download PDF Status: Published Journal Publication published 09 Jan, 2022 Read the published version in SN Comprehensive Clinical Medicine → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-203200","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":10741423,"identity":"cd7c7285-e16b-4cc4-b781-e8d3b7631e96","order_by":0,"name":"Hashim Ali Khan","email":"data:image/png;base64,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","orcid":"https://orcid.org/0000-0002-6538-2033","institution":"SEHHAT Foundation","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Hashim","middleName":"Ali","lastName":"Khan","suffix":""},{"id":10741424,"identity":"49ea4941-244d-4cfc-a0e0-8103aa72ff30","order_by":1,"name":"Muhammad Aamir Shahzad","email":"","orcid":"","institution":"Aziz Fatimah Medical and Dental College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Muhammad","middleName":"Aamir","lastName":"Shahzad","suffix":""},{"id":10741425,"identity":"790d2feb-8486-4fa9-bbcc-a4e7a67e8725","order_by":2,"name":"Junaid Iqbal","email":"","orcid":"","institution":"SEHHAT Foundation","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Junaid","middleName":"","lastName":"Iqbal","suffix":""},{"id":10741426,"identity":"1038c03e-a6f7-4249-95ea-e062704e0ab8","order_by":3,"name":"Sohail Abbas Juwa","email":"","orcid":"","institution":"SEHHAT Foundation Hospital","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sohail","middleName":"Abbas","lastName":"Juwa","suffix":""},{"id":10741427,"identity":"8f06619e-5580-47cc-a539-af8d775b7a56","order_by":4,"name":"Qaim Ali Khan","email":"","orcid":"","institution":"Poonch Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Qaim","middleName":"Ali","lastName":"Khan","suffix":""},{"id":10741428,"identity":"47439ad8-bb99-4047-bf85-783de876fe16","order_by":5,"name":"Munib ur Rehman","email":"","orcid":"","institution":"Khawaja Muhammad Safdar Medical College","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Munib","middleName":"ur","lastName":"Rehman","suffix":""},{"id":10741429,"identity":"e630e1e3-d248-49f5-8d22-37176421ed38","order_by":6,"name":"Fatima Iqbal","email":"","orcid":"","institution":"UNSW: University of New South Wales","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Fatima","middleName":"","lastName":"Iqbal","suffix":""}],"badges":[],"createdAt":"2021-02-03 23:56:28","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-203200/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-203200/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s42399-021-01094-w","type":"published","date":"2022-01-10T04:42:23+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":5978898,"identity":"45812886-244e-43be-95e4-056c18946ba4","added_by":"auto","created_at":"2021-02-15 17:20:02","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":79371,"visible":true,"origin":"","legend":"Figure 1 shows the disease course in the current study. ","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-203200/v1/da730e167125625ab9c953ad.jpg"},{"id":5978527,"identity":"148b20c6-c01e-428c-8f29-eb093dcb4708","added_by":"auto","created_at":"2021-02-15 17:17:02","extension":"tif","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":13828,"visible":true,"origin":"","legend":"Figure 2 shows the impact of age and duration of hospitalization on ocular recovery time. ","description":"","filename":"Figure2.tif","url":"https://assets-eu.researchsquare.com/files/rs-203200/v1/5f6a5578dad3eeb63a867817.tif"},{"id":17147158,"identity":"02e87afc-56f8-48ef-840d-a18ac6e165e8","added_by":"auto","created_at":"2022-01-10 04:42:25","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":240292,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-203200/v1/d3d61fdf-37b7-4b3d-8073-948b686c39e3.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003eEyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19)\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCoronavirus disease 2019 (COVID-19) is the spectrum of clinical manifestations caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\u0026nbsp; SARS-CoV-2 is a member of Coronaviridae family.[1] The rapid transmission of the virus has caused a global pandemic with 91.8 million cases and 1.97 million deaths globally.[2]\u0026nbsp; While respiratory disease caused by this virus has been most emphasized; the virus may also affect other body systems and function.\u003c/p\u003e\n\u003cp\u003eOcular manifestations of SARS-CoV-2 have been described by several investigators. While ocular surface disease is the most common ophthalmic manifestation of this virus; retinal vascular changes, neuro-ophthalmological complication, and uveal inflammation are also seen in a small number of patients.[3-5]\u003c/p\u003e\n\u003cp\u003eEyelid myokymia is the most common type of facial myokymias seen in otherwise healthy individuals. It is a self-limiting benign condition seen involuntary, fine, continuous, undulating contractions of orbicularis oculi muscles and may be associated with anxiety, depression, heavy caffeine intake and drugs.[6-8]\u003c/p\u003e\n\u003cp\u003eNevertheless, there are no reports in literature at this time, to the best of our knowledge, about the eyelid myokymia in COVID-19 patients. The objective of our study was to describe features of lid myokymia developed during or immediately after the recovery from systemic disease.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eIn this multicenter study, a cohort of patients who developed eyelid twitching during or after COVID-19 infection was recruited. Inclusion criteria were (1) New-onset eyelid twitching during or after active COVID-19 infection (2) age between 18 and 70 years, (3) Documented evidence of recovery from COVID-19 infection,\u003c/p\u003e\n\u003cp\u003eWe excluded patients who had (1) History of eyelid twitching within past 1 year, (2) history of ocular surgery or trauma within the past one year, (3) family history of essential blepharospasm or hemifacial spasm, (4) history of any ocular disease including glaucoma, uveitis or ocular surface disorders, and (5) history of head/ face trauma or any known neurological disease.\u003c/p\u003e\n\u003cp\u003eAll, time intervals were calculated from the date of discharge from hospital or documented recovery of systemic infection.\u003c/p\u003e\n\u003cp\u003eEach patient was evaluated at baseline and every month for 3 months. Comprehensive ophthalmic and neurological assessments including complete cranial nerve assessments were performed at each visit.\u003c/p\u003e\n\u003cp\u003eEyelid myokymia was defined as episodic or persistent fine, spontaneous undulating contraction involving any of upper or lower lids. The rate of occurrence was reported by the patient and graded as (1) most of the time, (2) half of the time, (3) sometimes or (4) none of the time. Resolution of lid myokymia was defined as the patient-reported complete absence of lid twitch for 2 weeks.\u0026nbsp; Myokymia recovery time was the interval between the systemic disease recovery and complete resolution of myokymia\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData analysis;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMicrosoft Excel was used for data collection and handling while Statistical analysis was performed using statistical software (SPSS software Version 21; SPSS, Inc., Chicago, IL, USA). Data were presented as mean \u0026plusmn;SD for quantitative variables and as counts (percentages) for categorical variables. Shapiro\u0026ndash;Wilk test was used to analyze the normal distribution of data. The effect of gender and hospital admission on ocular recovery interval was tested. The relationship between length of hospital stay and ocular recovery time was analyzed using Pearson (\u003cem\u003er\u003c/em\u003e) correlation. P values of \u0026lt; 0.05 were considered as statistically significant.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 15 patients, 9 (60%) males, were included. Mean\u0026plusmn; SD age was 48.3 \u0026plusmn; 7.9 (range 38 t0 62) years. There was no difference in age between males and females (P=0.81). Ten (66.7%) patients, 3 females and 7 males, had a history of hospital admission for management of COVID 19 disease. Mean duration of hospital stay was 6.7\u0026plusmn; 2.98 days (Range 3.0 to 13) while females had a shorter hospital stay 7.4\u0026plusmn;3.21 days vs 5.0\u0026plusmn;1.7 days (P=0.41). Five (33.3%) patients had a history of conjunctivitis during active systemic disease.\u0026nbsp; All patients experienced lid myokymia during or immediately after the systemic disease recovery. None of them had any neurological signs/ symptoms during or before the current study. Interval between systemic disease recovery baseline ocular examination was 13.1 \u0026plusmn; 4.5 days (range 7 to 21).\u0026nbsp; Patient demographics and clinical characteristics are shown in table 1.\u003c/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1:\u003c/strong\u003e Patient demographics, clinical characteristics and myokymia recovery time\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003ePatient\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eAge/Sex\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eHospitalized\u003c/p\u003e\n\u003cp\u003e/days\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eOcular Examination\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eConjunctivitis\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eRecovery time\u003c/p\u003e\n\u003cp\u003eDays\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e38/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/ 3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e19\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e31\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e44/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/ 4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e60\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e41/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo/0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e21\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e42/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo/0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e33\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e62/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/13\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eDidn\u0026rsquo;t recover*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e61/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eDidn\u0026rsquo;t recover*\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e46/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e21\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e49\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e47/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e42\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e53/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e88\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e55/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e62\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e11\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e57/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e18\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e67\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e12\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e51/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo/0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e43\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e13\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e40/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo/0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e16\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e18\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e49/F\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eYes/4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e10\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e40\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e15\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e39/M\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo/0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003eNo\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd\u003e\n\u003cp\u003e19\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp\u003e*Did not recover till the end point of current study\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAt baseline, most patients had been experiencing lid myokymia half of the time or most of the time. At one-month follow-up, most patients had been experiencing myokymia sometimes while 11 patients (73%) had complete resolution at two months follow-up. Thirteen patients (86.7%) had complete resolution at 3 months follow up. Figure 1 shows the disease course in the current study.\u003c/p\u003e\n\u003cp\u003eComplete recovery of lid myokymia was observed in 13 (87%) patients at three months post COVID-19 recovery. The interval between systemic disease recovery and complete resolution of lid myokymia was 44.1\u0026plusmn; 20.84 days. Two patients (1 male), did not report any improvement or deterioration of twitch at three months. Magnetic resonance imaging of the brain in those patients was unremarkable. Myokymia recovery interval was independent of the history of conjunctivitis (P=0.45) and gender (P=0.2).\u0026nbsp; There was a strong positive correlation between age and myokymia recovery time (\u003cem\u003er\u003c/em\u003e= 0.8, P=0.001). Length of hospitalization also had a positive correlation with myokymia recovery time (\u003cem\u003er=\u003c/em\u003e 0.8, P= 0.01).\u0026nbsp; Myokymia recovery time was independent of gender (t=1.5, df=11, P=0.2). Figure 2 shows the impact of age and duration of hospitalization on ocular recovery time.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eCommon ocular complications/ manifestations of COVID-19 include dry eye, non-specific conjunctivitis, and retinal vascular changes. The exact incidence of these complications is yet to be determined. However, ocular surface disorders including conjunctivitis and dry eye are most frequently reported in COVID-19 patients.[5,9,10,3] Non-specific conjunctivitis, including conjunctival hyperemia, lacrimation, follicular conjunctivitis, ocular pain have been reported in 5 to 31% of patients.[11-14] While ocular surface diseases ranging from conjunctivitis to keratopathy was seen in up to 60% of critically ill patients.[15,16] Other relatively common ocular manifestations of SARS-CoV-2 include keratoconjunctivitis, epithelial defects subepithelial infiltrates and pseudodendrites.[17,18,10]\u003c/p\u003e\n\u003cp\u003eGranulomatous anterior uveitis, retinal detachment, retinal vasculitis, retinitis, and retinal degenerations are seen in animal studies.[4,5,10] In a study of 54 COVID-19 patients, dilatation of retinal veins and vascular tortuosity were most common and seen in 27.7% and 12.9% of patients. Other changes included retinal hemorrhages in 9.25% and cotton wool spots in 7.4% of patients.[17] Another study reported hyperreflective foci in the macula of 12 COVID-19 patients using optical coherence tomography. Besides OCT findings, 4 patients had cotton wool spots and retinal microhemorrhages.[18] Concerns about the potential misinterpretation of these results have recently been posed, signifying that hyperreflective areas could merely represent normal retinal vessels.[19,20] Retinal vein occlusion and valsalva retinopathy are rare potential associations of COVID-19.[11]\u0026nbsp; Neuroophthalmological associations of SARS-CoV-2 are rare. A limited number of case reports have described Miller Fisher syndrome, Guillain-Barr\u0026eacute; syndrome, polyneuritis cranialis, internuclear ophthalmoparesis and oculomotor palsy.[5] Meningitis, encephalomyelitis and encephalopathy may also affect these patients.[10,21]\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;The primary outcome of the present study was to evaluate the pattern of eyelid myokymia presumably associated with COVID-19 and to the best of our knowledge, it is the first study to reporting eyelid myokymia as a potential association of SARS-CoV-2 infection.\u0026nbsp; We included all patients who experienced lid twitching during or after recovery from covid-19 infection.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe frequency/rate of myokymia gradually declined over time to total resolution and most patients completely recovered within two months of recovery from systemic disease. Older age and longer hospital stay were associated with prolongation of lid myokymia while the history of conjunctivitis had no impact on the time for recovery of myokymia.\u003c/p\u003e\n\u003cp\u003eEyelid myokymia results from doublets or triplets of spontaneous non-synchronous discharges of adjacent motor units at a 30 to 70 Hz rate with inter-discharge intervals of 100-200 ms.[8,22] It is most common of all facial myokymias, typically unilateral with a tendency for lower lid and limited to orbicularis oculi muscle. It is a self-limiting benign condition affecting otherwise healthy individuals at any age and resolves completely over days to months.[23,8,6] Nonetheless stress, anxiety, excessive caffeine intake and administration of topiramate are known associations.[24,7,8] Rarely it may be associated with Guillain‐Barre syndrome and multiple sclerosis.[25,26] Mental illness including anxiety and depression are common, affecting roughly 1/4\u003csup\u003eth\u003c/sup\u003e to half of the COVID-19 survivors, immediate post-recovery and may persist for long. The incidence of mental illness was greater in hospitalized patients.[27,28,1,29,30] None of our patients had a recent history of topiramate intake or heavy caffeine consumption. Nonetheless, eyelid myokymia in our cohort of patients is attributable to anxiety or presumably it is a manifestation of SARS-CoV-2 infection itself. Akin to classic eyelid myokymia, there was a gradual recovery of myokymia in our patients. While older age and hospitalization were associated with slower resolution of the disease.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eYamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, Cushing TR, Hopp L, Tiwari A, Hariri R, Sokolov R, Wheeler C, Kaushik A, Elsayegh A, Eliashiv D, Hedrick R, Jafari B, Johnson JP, Khorsandi M, Gonzalez N, Balakhani G, Lahiri S, Ghavidel K, Amaya M, Kloor H, Hussain N, Huang E, Cormier J, Wesson Ashford J, Wang JC, Yaghobian S, Khorrami P, Shamloo B, Moon C, Shadi P, Kateb B (2020) COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. J Alzheimers Dis 77 (2):459-504. doi:10.3233/jad-200831\u003c/li\u003e\n\u003cli\u003eWHO Coronavirus Disease (COVID-19) Dashboard. (2021). \u003ca href=\"https://covid19.who.int/\"\u003ehttps://covid19.who.int/\u003c/a\u003e. Accessed 12/01/2021 2021\u003c/li\u003e\n\u003cli\u003eBostanci Ceran B, Ozates S (2020) Ocular manifestations of coronavirus disease 2019. Graefes Arch Clin Exp Ophthalmol 258 (9):1959-1963. doi:10.1007/s00417-020-04777-7\u003c/li\u003e\n\u003cli\u003eSeah I, Agrawal R (2020) Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm 28 (3):391-395. doi:10.1080/09273948.2020.1738501\u003c/li\u003e\n\u003cli\u003eBertoli F, Veritti D, Danese C, Samassa F, Sarao V, Rassu N, Gambato T, Lanzetta P (2020) Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. J Ophthalmol 2020:4827304. doi:10.1155/2020/4827304\u003c/li\u003e\n\u003cli\u003eBanik R, Miller NR (2004) Chronic Myokymia Limited to the Eyelid Is a Benign Condition. J Neuroophthalmol 24 (4):290-292\u003c/li\u003e\n\u003cli\u003eKhalkhali M (2016) Topiramate-Induced Persistent Eyelid Myokymia. Case Reports in Psychiatry 2016:7901085. doi:10.1155/2016/7901085\u003c/li\u003e\n\u003cli\u003eMiller NR (2011) Eyelid Myokymia. Surv Ophthalmol 56 (3):277-278. doi:10.1016/j.survophthal.2011.02.005\u003c/li\u003e\n\u003cli\u003eSun S, Su W, Lin CQ, Li X, Yan H, Tian B, Lin H (2020) COVID-19: the novel coronavirus disease and its manifestations and management in ophthalmology. Discov Med 29 (158):145-157\u003c/li\u003e\n\u003cli\u003eHo D, Low R, Tong L, Gupta V, Veeraraghavan A, Agrawal R (2020) COVID-19 and the Ocular Surface: A Review of Transmission and Manifestations. Ocul Immunol Inflamm 28 (5):726-734. doi:10.1080/09273948.2020.1772313\u003c/li\u003e\n\u003cli\u003eWu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K (2020) Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol 138 (5):575-578. doi:10.1001/jamaophthalmol.2020.1291\u003c/li\u003e\n\u003cli\u003eChen L, Deng C, Chen X, Zhang X, Chen B, Yu H, Qin Y, Xiao K, Zhang H, Sun X (2020) Ocular manifestations and clinical characteristics of 535 cases of COVID-19 in Wuhan, China: a cross-sectional study. Acta Ophthalmol 98 (8):e951-e959. doi:10.1111/aos.14472\u003c/li\u003e\n\u003cli\u003eG\u0026uuml;emes-Villahoz N, Burgos-Blasco B, Garc\u0026iacute;a-Feijo\u0026oacute; J, S\u0026aacute;enz-Franc\u0026eacute;s F, Arriola-Villalobos P, Martinez-de-la-Casa JM, Ben\u0026iacute;tez-Del-Castillo JM, Herrera de la Muela M (2020) Conjunctivitis in COVID-19 patients: frequency and clinical presentation. Graefes Arch Clin Exp Ophthalmol 258 (11):2501-2507. doi:10.1007/s00417-020-04916-0\u003c/li\u003e\n\u003cli\u003eSindhuja K, Lomi N, Asif MI, Tandon R (2020) Clinical profile and prevalence of conjunctivitis in mild COVID-19 patients in a tertiary care COVID-19 hospital: A retrospective cross-sectional study. Indian J Ophthalmol 68 (8):1546-1550. doi:10.4103/ijo.IJO_1319_20\u003c/li\u003e\n\u003cli\u003eSaritas TB, Bozkurt B, Simsek B, Cakmak Z, Ozdemir M, Yosunkaya A (2013) Ocular Surface Disorders in Intensive Care Unit Patients. Scientific World Journal 2013:182038. doi:10.1155/2013/182038\u003c/li\u003e\n\u003cli\u003eMercieca F, Suresh P, Morton A, Tullo A (1999) Ocular surface disease in intensive care unit patients. Eye 13 (2):231-236. doi:10.1038/eye.1999.57\u003c/li\u003e\n\u003cli\u003eInvernizzi A, Torre A, Parrulli S, Zicarelli F, Schiuma M, Colombo V, Giacomelli A, Cigada M, Milazzo L, Ridolfo A, Faggion I, Cordier L, Oldani M, Marini S, Villa P, Rizzardini G, Galli M, Antinori S, Staurenghi G, Meroni L (2020) Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine 27. doi:10.1016/j.eclinm.2020.100550\u003c/li\u003e\n\u003cli\u003eMarinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R, Jr. (2020) Retinal findings in patients with COVID-19. The Lancet 395 (10237):1610. doi:10.1016/S0140-6736(20)31014-X\u003c/li\u003e\n\u003cli\u003eKhan HA, Shahzad MA, Awan MA, Marashi A (2020) Perspective on retinal findings in COVID-19. Adv Ophthalmol Vis Syst 10 (5):121-122\u003c/li\u003e\n\u003cli\u003eVavvas DG, Sarraf D, Sadda SR, Eliott D, Ehlers JP, Waheed NK, Morizane Y, Sakamoto T, Tsilimbaris M, Miller JB (2020) Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication. Eye 34 (12):2153-2154. doi:10.1038/s41433-020-1084-9\u003c/li\u003e\n\u003cli\u003eYavarpour-Bali H, Ghasemi-Kasman M (2020) Update on neurological manifestations of COVID-19. Life sciences 257:118063-118063. doi:10.1016/j.lfs.2020.118063\u003c/li\u003e\n\u003cli\u003eHorowitz SH (1987) Hemifacial spasm and facial myokymia: electrophysiological findings. Muscle Nerve 10 (5):422-427. doi:10.1002/mus.880100508\u003c/li\u003e\n\u003cli\u003eKim L, Levine B, Lelli G (2010) Recognition and treatment of benign essential blepharospasm and its variants. Contemporary Ophthalmology 9 (6):1-5\u003c/li\u003e\n\u003cli\u003eMedrano-Mart\u0026iacute;nez V, P\u0026eacute;rez-Sempere A, Molt\u0026oacute;-Jord\u0026aacute; JM, Fern\u0026aacute;ndez-Izquierdo S, Franc\u0026eacute;s-Pont I, Mallada-Frechin J, Piqueras-Rodr\u0026iacute;guez L (2015) Eyelid myokymia in patients with migraine taking topiramate. Acta Neurol Scand 132 (2):143-146. doi:\u003ca href=\"https://doi.org/10.1111/ane.12395\"\u003ehttps://doi.org/10.1111/ane.12395\u003c/a\u003e\u003c/li\u003e\n\u003cli\u003ePalas\u0026iacute; A, Mart\u0026iacute;nez-S\u0026aacute;nchez N, Bau L, Campdelacreu J (2013) Unilateral eyelid myokymia as a form of presentation of multiple sclerosis. Neurolog\u0026iacute;a (English Edition) 28 (3):187-189. doi:10.1016/j.nrleng.2011.09.009\u003c/li\u003e\n\u003cli\u003eVan Zandycke M, Martin J-J, Gaer LV, Van den Heyning P (1982) Facial myokymia in the Guillain‐Barre syndrome: A clinicopathologic study. Neurology 32 (7):744-744\u003c/li\u003e\n\u003cli\u003eMazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, Melloni EMT, Furlan R, Ciceri F, Rovere-Querini P, group C-BOCS, Benedetti F (2020) Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun 89:594-600. doi:10.1016/j.bbi.2020.07.037\u003c/li\u003e\n\u003cli\u003eDai L-L, Wang X, Jiang T-C, Li P-F, Wang Y, Wu S-J, Jia L-Q, Liu M, An L, Cheng Z (2020) Anxiety and depressive symptoms among COVID-19 patients in Jianghan Fangcang Shelter Hospital in Wuhan, China. PLoS One 15 (8):e0238416. doi:10.1371/journal.pone.0238416\u003c/li\u003e\n\u003cli\u003eRogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7 (7):611-627. doi:10.1016/S2215-0366(20)30203-0\u003c/li\u003e\n\u003cli\u003eKeyhanian K, Umeton RP, Mohit B, Davoudi V, Hajighasemi F, Ghasemi M (2020) SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation. J Neuroimmunol 350:577436-577436. doi:10.1016/j.jneuroim.2020.577436\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"COVID-19, eyelid myokymia, corona virus, blepharospasm","lastPublishedDoi":"10.21203/rs.3.rs-203200/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-203200/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003ePurpose\u003c/h2\u003e \u003cp\u003eTo report the eyelid myokymia in patients recovered from COVID-19 disease.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA cohort of 15 patients who developed eyelid myokymia during or immediate post-recovery of systemic disease were evaluated. Demographic, clinical characteristics, effect of age, and hospitalization on the disease course were studied. The disease course was evaluated every month for 3 months period.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAll, except 2, patients had complete resolution of lid myokymia within 3 months of onset. Mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD myokymia recovery time was 44.1\u0026thinsp;\u0026plusmn;\u0026thinsp;20.9 Days. Gender had no impact on the duration of disease. Age and duration of hospitalization had a strong positive correlation with myokymia recovery time (r\u0026thinsp;=\u0026thinsp;0.8, p\u0026thinsp;=\u0026thinsp;0.001 and r\u0026thinsp;=\u0026thinsp;0.8, p\u0026thinsp;=\u0026thinsp;0.01).\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eEyelid myokymia may involve COVID-19 patients during or immediately after systemic recovery. While myokymia recovers gradually in all these patients; older age and longer duration of hospitalization are associated with slower recovery.\u003c/p\u003e","manuscriptTitle":"Eyelid Myokymia as a presumed manifestation of Coronavirus Disease 2019 (COVID-19)","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2021-02-15 17:17:00","doi":"10.21203/rs.3.rs-203200/v1","editorialEvents":[{"type":"communityComments","content":2}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"e27f07d9-628b-410c-81d8-3f6c9c5f0308","owner":[],"postedDate":"February 15th, 2021","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":2427252,"name":"Ophthalmology"}],"tags":[],"updatedAt":"2022-01-10T04:42:23+00:00","versionOfRecord":{"articleIdentity":"rs-203200","link":"https://doi.org/10.1007/s42399-021-01094-w","journal":{"identity":"sn-comprehensive-clinical-medicine","isVorOnly":false,"title":"SN Comprehensive Clinical Medicine"},"publishedOn":"2022-01-10 04:42:23","publishedOnDateReadable":"January 10th, 2022"},"versionCreatedAt":"2021-02-15 17:17:00","video":"","vorDoi":"10.1007/s42399-021-01094-w","vorDoiUrl":"https://doi.org/10.1007/s42399-021-01094-w","workflowStages":[]},"version":"v1","identity":"rs-203200","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-203200","identity":"rs-203200","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}